Celltrion Pharm Inc banner
C

Celltrion Pharm Inc
KOSDAQ:068760

Watchlist Manager
Celltrion Pharm Inc
KOSDAQ:068760
Watchlist
Price: 56 000 KRW 0.54% Market Closed
Market Cap: ₩2.5T

Gross Margin

29.2%
Current
Improving
by 0.6%
vs 3-y average of 28.6%

Gross Margin shows how much money a company keeps from each dollar of sales after paying for the products it sells. It tells how profitable the company`s core business is before other expenses.

Gross Margin
29.2%
=
Gross Profit
₩151.1B
/
Revenue
₩517.6B

Gross Margin shows how much money a company keeps from each dollar of sales after paying for the products it sells. It tells how profitable the company`s core business is before other expenses.

Gross Margin
29.2%
=
Gross Profit
₩151.1B
/
Revenue
₩517.6B

Peer Comparison

Country Company Market Cap Gross
Margin
KR
Celltrion Pharm Inc
KOSDAQ:068760
2.5T KRW
Loading...
US
Eli Lilly and Co
NYSE:LLY
887.6B USD
Loading...
US
Johnson & Johnson
NYSE:JNJ
574.2B USD
Loading...
UK
AstraZeneca PLC
LSE:AZN
236.2B GBP
Loading...
CH
Roche Holding AG
SIX:ROG
248.4B CHF
Loading...
US
Merck & Co Inc
NYSE:MRK
300.5B USD
Loading...
CH
Novartis AG
SIX:NOVN
234.4B CHF
Loading...
IE
Endo International PLC
LSE:0Y5F
244.4B USD
Loading...
DK
Novo Nordisk A/S
CSE:NOVO B
1.1T DKK
Loading...
US
Pfizer Inc
NYSE:PFE
153.1B USD
Loading...
US
Bristol-Myers Squibb Co
NYSE:BMY
118B USD
Loading...

Market Distribution

In line with most companies in Korea
Percentile
66th
Based on 2 511 companies
66th percentile
29.2%
Low
-646.5% — 12.8%
Typical Range
12.8% — 32.2%
High
32.2% — 54 001.3%
Distribution Statistics
Korea
Min -646.5%
30th Percentile 12.8%
Median 19.7%
70th Percentile 32.2%
Max 54 001.3%

Celltrion Pharm Inc
Glance View

Market Cap
2.5T KRW
Industry
Pharmaceuticals

In the bustling world of pharmaceuticals, Celltrion Pharm Inc. has carved a niche for itself, leveraging innovation and strategic market positioning. Born out of South Korea, this dynamic player operates with a vision to transform the pharmaceutical landscape, particularly through its expertise in biosimilars and small molecule drugs. By focusing on cutting-edge research and development, Celltrion Pharm is able to produce high-quality, cost-effective alternatives to branded biologics, which are essential for treating diseases such as cancer and autoimmune disorders. With a comprehensive pipeline of biosimilar products, the company effectively taps into a growing demand, driven by global healthcare systems seeking cost-efficient therapeutics amidst rising healthcare expenditures. Celltrion Pharm's operational strategy extends beyond product innovation. It encompasses robust manufacturing infrastructure and a global distribution network that underscores its financial growth. By owning state-of-the-art production facilities, the company ensures both the scale and quality required to meet international benchmarks, which is pivotal in the highly regulated pharmaceutical industry. Furthermore, strategic alliances and partnerships bolster its market reach, ensuring that its products have strong footholds not just locally, but globally. Through these multifaceted endeavors—ranging from R&D to distribution—the company has positioned itself as a formidable force, achieving sustainable revenue streams by addressing critical healthcare needs and optimizing drug accessibility worldwide.

Intrinsic Value
25 420.12 KRW
Overvaluation 55%
Intrinsic Value
Price ₩56 000
C
What is Gross Margin?
Gross Margin shows how much money a company keeps from each dollar of sales after paying for the products it sells. It tells how profitable the company`s core business is before other expenses.
How is Gross Margin calculated?

Gross Margin is calculated by dividing the Gross Profit by the Revenue.

Gross Margin
29.2%
=
Gross Profit
₩151.1B
/
Revenue
₩517.6B
What is Celltrion Pharm Inc's current Gross Margin?

The current Gross Margin for Celltrion Pharm Inc is 29.2%, which is above its 3-year median of 28.6%.

How has Gross Margin changed over time?

Over the last 3 years, Celltrion Pharm Inc’s Gross Margin has increased from 28.5% to 29.2%. During this period, it reached a low of 25.5% on Dec 31, 2024 and a high of 31.1% on Jun 30, 2023.

Back to Top
Get AI-powered insights for any company or topic.
Open AI Assistant

Intrinsic Value is all-important and is the only logical way to evaluate the relative attractiveness of investments and businesses.

Warren Buffett